↓ Skip to main content

Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet

Overview of attention for article published in Blood, October 2013
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (93rd percentile)
  • High Attention Score compared to outputs of the same age and source (96th percentile)

Mentioned by

news
1 news outlet
twitter
11 tweeters
patent
6 patents

Citations

dimensions_citation
356 Dimensions

Readers on

mendeley
306 Mendeley
citeulike
2 CiteULike
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet
Published in
Blood, October 2013
DOI 10.1182/blood-2013-03-492884
Pubmed ID
Authors

Luca Malcovati, Eva Hellström-Lindberg, David Bowen, Lionel Adès, Jaroslav Cermak, Consuelo del Cañizo, Matteo G. Della Porta, Pierre Fenaux, Norbert Gattermann, Ulrich Germing, Joop H. Jansen, Moshe Mittelman, Ghulam Mufti, Uwe Platzbecker, Guillermo F. Sanz, Dominik Selleslag, Mette Skov-Holm, Reinhard Stauder, Argiris Symeonidis, Arjan A. van de Loosdrecht, Theo de Witte, Mario Cazzola

Abstract

Within the myelodysplastic syndrome (MDS) work package of the European LeukemiaNet, an Expert Panel was selected according to the framework elements of the National Institutes of Health Consensus Development Program. A systematic review of the literature was performed that included indexed original papers, indexed reviews and educational papers, and abstracts of conference proceedings. Guidelines were developed on the basis of a list of patient- and therapy-oriented questions, and recommendations were formulated and ranked according to the supporting level of evidence. MDSs should be classified according to the 2008 World Health Organization criteria. An accurate risk assessment requires the evaluation of not only disease-related factors but also of those related to extrahematologic comorbidity. The assessment of individual risk enables the identification of fit patients with a poor prognosis who are candidates for up-front intensive treatments, primarily allogeneic stem cell transplantation. A high proportion of MDS patients are not eligible for potentially curative treatment because of advanced age and/or clinically relevant comorbidities and poor performance status. In these patients, the therapeutic intervention is aimed at preventing cytopenia-related morbidity and preserving quality of life. A number of new agents are being developed for which the available evidence is not sufficient to recommend routine use. The inclusion of patients into prospective clinical trials is strongly recommended.

Twitter Demographics

The data shown below were collected from the profiles of 11 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 306 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 2 <1%
Peru 1 <1%
Netherlands 1 <1%
Ireland 1 <1%
Belgium 1 <1%
Spain 1 <1%
Japan 1 <1%
United States 1 <1%
Unknown 297 97%

Demographic breakdown

Readers by professional status Count As %
Other 57 19%
Researcher 46 15%
Student > Ph. D. Student 45 15%
Student > Postgraduate 30 10%
Student > Master 27 9%
Other 76 25%
Unknown 25 8%
Readers by discipline Count As %
Medicine and Dentistry 195 64%
Biochemistry, Genetics and Molecular Biology 30 10%
Agricultural and Biological Sciences 20 7%
Pharmacology, Toxicology and Pharmaceutical Science 7 2%
Nursing and Health Professions 5 2%
Other 19 6%
Unknown 30 10%

Attention Score in Context

This research output has an Altmetric Attention Score of 25. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 04 May 2020.
All research outputs
#789,735
of 15,175,922 outputs
Outputs from Blood
#793
of 25,317 outputs
Outputs of similar age
#11,282
of 186,582 outputs
Outputs of similar age from Blood
#13
of 401 outputs
Altmetric has tracked 15,175,922 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 94th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 25,317 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.5. This one has done particularly well, scoring higher than 96% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 186,582 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 93% of its contemporaries.
We're also able to compare this research output to 401 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 96% of its contemporaries.